Tenderwize
Retour à la recherche

Open house Arzneimittelrabattverträge Betamethason und Fusidinsäure, ATC D07CC01

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Apr 05, 2027 · 219 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Betamethason und Fusidinsäure, ATC D07CC01

50/100

Score d'opportunité

PromisingLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

If a federal or state-level rebate contract for Betamethason and Fusidinsäure is concluded, the open-house agreements a...

Submission rules are detailed: paper copies must be submitted in duplicate, and electronic submissions require qualifie...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Strong opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Non-exclusive pharmaceutical rebate agreements for Betamethason and Fusidinsäure (ATC D07CC01) under § 130a Abs. 8 SGB V.
  • Open-house model: all qualified pharmaceutical companies may sign identical, non-negotiable rebate contracts.
Afficher le résumé complet

Open-house model for non-exclusive pharmaceutical rebate agreements on Betamethason and Fusidinsäure (ATC D07CC01) with AOK Bayern. All qualified pharmaceutical companies may join. Contract runs from 01.06.2025 to 31.05.2027, with rolling entry. No estimated value provided. No award criteria; eligibility based solely on a signed self-declaration of reliability.

Risques

If a federal or state-level rebate contract for Betamethason and Fusidinsäure is concluded, the open-house agreements a...

Submission rules are detailed: paper copies must be submitted in duplicate, and electronic submissions require qualifie...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Eligibility: Only pharmaceutical companies (pharmazeutische Unternehmen) may participate.

Administrative

  • Submission of completed and signed contract, annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and signed self-declaration of reliability.
  • Submission in paper form (2 copies) or electronically with qualified electronic signature.

Les exigences peuvent être incomplètes.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house Arzneimittelrabattverträge Betamethason und Fusidinsäure, ATC D07CC01

Non-exclusive rebate agreements for pharmaceutical products with active ingredients Betamethason and Fusidinsäure, ATC code D07CC01. Place of performance: Bavaria, Germany. Contract type: supplies. Framework agreement with no maximum value stated.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

May 2025 - May 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Apr 05, 2027

Détails de la procédure

Date de publication
15 Apr 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
250356-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30